Dow Up0.08% Nasdaq Down0.30%

Vical Incorporated (VICL)

1.16 0.00(0.00%) Sep 19, 4:00PM EDT
|After Hours : 1.16 0.00 (0.00%) Sep 19, 4:00PM EDT
ProfileGet Profile for:
Vical Incorporated
10390 Pacific Center Court
San Diego, CA 92121
United States - Map
Phone: 858-646-1100
Fax: 858-646-1150

Index Membership:N/A
Full Time Employees:67

Business Summary 

Vical Incorporated is engaged in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex virus type 2, which are under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing TransVax, which is in Phase III clinical trial to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it is also engaged in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Vical Incorporated

Corporate Governance 
Vical Incorporated’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Vijay B. Samant , 61
Chief Exec. Officer, Pres, Acting Chief Financial Officer and Director
Mr. Anthony Alan Ramos , 47
Chief Accounting Officer and VP Fin.
Dr. Igor P. Bilinsky Ph.D., 41
Sr. VP of Corp. Devel.
Dr. Lawrence Russell Smith Ph.D., 53
VP of Vaccine Research
Dr. Mammen P. Mammen Jr., M.D., 50
VP of Clinical Vaccines
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders